Quick Answer
Whitehawk Therapeutics, Inc. reported Operating Income of -$114.40 million for fiscal year 2025.
Whitehawk Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$114.40M | -69.6% |
| 2024 | -$67.46M | +6.2% |
| 2023 | -$71.93M | -14.8% |
| 2022 | -$62.68M | +43.6% |
| 2021 | -$111.22M | -4263.2% |
| 2020 | -$2.55M | +89.6% |
| 2019 | -$24.44M | -118.6% |
| 2018 | -$11.18M | +47.7% |
| 2017 | -$21.39M | -28.6% |
| 2016 | -$16.63M | -72201.1% |
| 2015 | -$23.0K | +4.0% |
| 2014 | -$24.0K | -5.0% |
| 2013 | -$22.8K | -1.9% |
| 2012 | -$22.4K | +5.1% |
| 2011 | -$23.6K | -15.0% |
| 2010 | -$20.5K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.55M | -45.7% | +64.3% |
| June 30, 2025 | -$54.75M | -251.3% | -259.8% |
| March 31, 2025 | -$15.22M | +22.0% | -13.5% |
| September 30, 2024 | -$13.41M | +24.9% | +13.9% |
| June 30, 2024 | -$15.58M | +20.3% | +20.1% |
| March 31, 2024 | -$19.51M | -16.0% | -9.3% |
| September 30, 2023 | -$17.85M | -18.7% | +8.7% |
| June 30, 2023 | -$19.55M | -6.5% | -16.2% |
- Whitehawk Therapeutics, Inc. showed a decrease of -69.6% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Whitehawk Therapeutics, Inc.’s operating income has declined by 557703.9% (from -$20.5 thousand to -$114.40 million).
- The most recent figure is from Whitehawk Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: